Skip to content

Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis

Safety and Efficacy of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00691314
Acronym
ESSCAS
Enrollment
300
Registered
2008-06-05
Start date
2008-06-30
Completion date
2010-12-31
Last updated
2011-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Stenosis, Stents, Stroke, Transient Ischemic Attack

Keywords

Stroke, Transietn Ischemic Attack, Stents, Stenosis

Brief summary

The purpose of this study is to evaluate the efficacy and safety of stent implantation in patients with symptomatic extra- and intracranial artery stenosis and to determine its role in secondary prevention of ischemic stroke.

Interventions

DEVICEStent implantation (Wingspan, Coroflex, and TiTAN2)

Stent Implantation: Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex® - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent Standard Medical Management:including antiplatelet agents(Aspirin 75\ 150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) . Arms: 1

DRUGStandard medical treatment

Standard Medical Management:including antiplatelet agents(Aspirin 75\ 150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Aged between above 40 year-old and 75 year-old. 2. Ischemic stroke related to extra- and intracranial atherosclerosis stenosis, transient ischemic attack (TIA ), onset time within 90 days 3. Implantation of stent should be at least 1 week after stroke onset, and patient's medical condition stable, no time limit for TIA, 4. Stenosed ICA or MCA or BA or VA is the candidate arteries for stent implantation. 5. Degree of stenosis of target artery ranges between 51%-99% 6. Modified Rankin score≤3 or NIHSS Score ≤4 7. Informed consent is obtained.

Exclusion criteria

Patients will be excluded from entry if any of the criteria listed below are met: 1. Target stenosis artery is not suitable for stent implantation after evaluation. 2. Previous carotid endarterectomy or carotid artery stent ,or intracranial artery stent implantation. 3. Ischemic stroke is caused by conditions other than atherosclerosis . 4. Documented non-atherosclerosis angiopathy. 5. Clinically unstable at the time of enrollment, 6. Conditions which may lead to cardiogenic embolism : arterial fibrillation,left ventricular thrombi,Myocardiac infarction within 6 weeks,etc. 7. Severe hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg) 8. Severe co-morbid or unstable medical condition, ie,severe heart failure, pulmonary failure or renal failure, liver dysfunction (serum liver enzyme twice or more than normal level),malignancy with likelihood of death within the next 2 years 9. Significant memory or behavioral disorder, ie, Alzheimer disease, etc.daily care needed. 10. Concurrent participation in another clinical trial 11. Unable to return follow up 12. History of hemorrhagic disease(ie, intracranial hemorrhage, Idiopathic Thrombocytopenic Purpura,etc ) or bleeding tendency conditions. 13. Intracranial arteriovenous malformation or aneurysm.

Design outcomes

Primary

MeasureTime frame
Ischemic stroke in the supply area of stent implantation artery30 days and 1 year after the procedure

Secondary

MeasureTime frame
Ischemic stroke in the supply area of non-stent implantation artery30 days and 1 year after the procedure
Acute coronary syndrome30 days and 1 year after the procedure
Hemorrhagic stroke30 days and 1 year after the procedure
Transient ischemic attack30 days and 1 year after the procedure
Degree of re-stenosis of the stent implantation artery30 days and 1 year after the procedure
All-cause death30 days and 1 year after the procedure

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026